Update on Partnership with 4TEEN4 Pharmaceuticals

Abingdon Health

06/05/2026 07:00

RNS Number : 1323D

Abingdon Health PLC

06 May 2026

 

 

Abingdon Health plc

("Abingdon Health", the "Group" or the "Company")

 

Update on Partnership with 4TEEN4 Pharmaceuticals

 

York, UK and Madison, WI, USA, 6 May 2026: Abingdon Health plc (AIM: ABDX) (OTCQB: ABDXF), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, provides an update on its partnership with 4TEEN4 Pharmaceuticals GmbH ("4TEEN4"), a German biopharmaceutical company developing invobenitug (procizumab, AK1967), a first-in-class antibody therapy for life-threatening cardiogenic and septic shock.

 

This partnership was first announced via RNS on 12 June 2025, without giving details of the customer or project at that time for confidentiality reasons.

 

As legal manufacturer and CDMO partner, Abingdon Health is developing DPP3 InvoSelect, a lateral flow-based companion diagnostic (CDx) designed to identify the patients most likely to benefit from this targeted therapy.

 

The project brings together Abingdon Health's core capabilities:

·    Lateral Flow Development: designing a scalable, easy-to-use assay with a customised reader for clear, unambiguous quantification of cDPP3 at the point of care.

·    Regulatory Expertise: proactively engaging with regulatory agencies for technical advice and ensuring CDx strategy is tightly aligned with the drug development pathway.

·    Manufacturing at Scale: building a test engineered for global distribution and consistent quality from day one.

·    Synchronised Co-development: matching every CDx milestone to the drug's clinical timeline, because in a project like this, the two cannot be decoupled.

 

The challenge of synchronising diagnostic and therapeutic development is incredibly complex and demands experienced technical capability, deep regulatory understanding, genuine partnership, and rigorous project management.

 

The full case study is available at: Case Study: 4TEEN4 Companion Diagnostic Partnership - Abingdon Health plc

 

The Head of CDx at 4TEEN4 Pharmaceuticals commented: "The technical expertise and regulatory support provided by Abingdon Health have been invaluable in advancing our companion diagnostic project. Their commitment and collaborative approach have brought us significantly closer to delivering a life-saving therapy for patients in critical shock."

 

Chris Yates, Chief Commercial Officer at Abingdon Health plc, commented: "Companion diagnostics that are tightly co-developed alongside a therapeutic aren't just a technical challenge; they represent a genuine opportunity to change patient outcomes. We're proud to be 4TEEN4's CDMO partner on this programme, and the progress we've made together in aligning our CDx milestones with their clinical pathway reflects the depth of collaboration both teams are committed to. We look forward to continuing to advance this project toward the patients who need it most."

 

Any shareholders wishing to keep up to date with Abingdon Health news, please email abingdon@walbrookpr.com

 

Enquiries:

 

Abingdon Health plc
www.abingdonhealth.com/investors/
Chris Hand, ExecutiveChairman
Via Walbrook PR
Tom Hayes, CFO
Cavendish Capital Markets Limited (Sole Broker and Nominated Adviser)
Tel: +44 (0)20 7220 0500
Geoff Nash / Isaac Hooper /Joe Smith(Corporate Finance)
Nigel Birks (Life Science Specialist Sales)
Walbrook PR (Media & Investor Relations)
Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
Paul McManus / Alice Woodings
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654


 

 

About Abingdon Health

 

Abingdon Health Group is a leading med-tech contract service provider offering its services to an international customer base.  

 

The Group's CDMO (Contract Development and Manufacturing Organisation) expertise offers lateral flow product development, regulatory strategy support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format.  Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from idea to commercial success.

 

Abingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Its consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring.  The Company's subsidiary, Abingdon Analytical Ltd, offers analytical testing and performance evaluation to generate the required technical and data for regulatory approval for lateral flow and other in vitro diagnostic assays from its Doncaster, England facilities.

 

Founded in 2008, Abingdon Health is headquartered in York, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA.

 

Abingdon Health's brochures outlines the comprehensive support the Group can now provide to its international customers.  For more information visit: www.abingdonhealth.com.

 

LEI - 213800XFI4WV3FBILO20

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NRAUPUPWAUPQGBA